DiaMedica Therapeutics Releases Preeclampsia White Paper And Announces Key Opinion Leader Webinar On DM199 For The Treatment Of Preeclampsia

7/11/24 8:14:33 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $DMAC alert in real time by email

Company to Host Preeclampsia Key Opinion Leader Event July 29, 2024 at 10 AM Eastern / 9 AM Central
White Paper: The Potential of DM199 to Treat Preeclampsia

DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic disease, today announced that it will host a virtual key opinion leader (KOL) event on Monday, July 29, 2024, at 10:00 AM ET to provide further insight into the expansion of its clinical development program for DM199 (rinvecalinase alfa) into preeclampsia, a significant, unmet medical need with no FDA-approved therapeutics.

Get the next $DMAC alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$DMAC

Date	Price Target	Rating	Analyst
10/7/2024	$7.00	Buy	H.C. Wainwright
4/24/2024	$8.00	Buy	Craig Hallum
6/22/2023	$7.00	Perform → Outperform	Oppenheimer
6/30/2021	$38.00 → $32.00	Buy	Roth Capital

More analyst ratings

DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2024 Financial Results
Conference Call and Webcast Thursday November 14 at 8:00 AM Eastern Time / 7:00 AM Central Time Implemented Updates to AIS Program Intended to Enhance Probability of Trial Success and Expedite Study Completion, with Potential for a Reduced Study Size Preeclampsia Phase 2 Trial Received Regulatory Approval and First Patient Dosed Cash Runway Into Q3 2026 DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today provided a business update and financial results for the quarter ended September 30, 2024. Management will host a conference call Thursday, November 14, 2024, at 8:00 AM
11/13/24 4:20:00 PM ET
$DMAC
Biotechnology: Pharmaceutical Preparations
Health Care
DiaMedica Therapeutics Announces Dosing of First Patient in Phase 2 Trial of DM199 in the Treatment of Preeclampsia
DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today announced that the first patient has been dosed in DiaMedica's investigator-sponsored Phase 2 trial of DM199 for the treatment of preeclampsia (PE). DiaMedica anticipates top line data for Part 1A in the first half of 2025 which is expected to demonstrate initial proof-of-concept including whether DM199 is safe and lowers blood pressure. Additionally, for patients with early onset PE, DiaMedica will be looking for improvements in uterine artery dilation, indicating that DM199 therapy is potentially disease modifying in these patient
11/13/24 4:05:00 PM ET
$DMAC
Biotechnology: Pharmaceutical Preparations
Health Care
DiaMedica Therapeutics to Participate in Upcoming Craig-Hallum 15th Annual Alpha Select Conference
DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, announced today that the Company's management will attend the 15th Annual Craig-Hallum Alpha Select Conference on Tuesday, November 19, 2024 in New York City, New York. Management will be available for one-on-one meetings throughout the day. Investors and attendees that would like to schedule a meeting with DiaMedica's management can contact their Craig-Hallum representative to arrange a meeting. About DiaMedica Therapeutics Inc. DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the liv
11/12/24 8:23:00 AM ET
$DMAC
Biotechnology: Pharmaceutical Preparations
Health Care

DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2024 Financial Results
Conference Call and Webcast Thursday November 14 at 8:00 AM Eastern Time / 7:00 AM Central Time Implemented Updates to AIS Program Intended to Enhance Probability of Trial Success and Expedite Study Completion, with Potential for a Reduced Study Size Preeclampsia Phase 2 Trial Received Regulatory Approval and First Patient Dosed Cash Runway Into Q3 2026 DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today provided a business update and financial results for the quarter ended September 30, 2024. Management will host a conference call Thursday, November 14, 2024, at 8:00 AM
11/13/24 4:20:00 PM ET
$DMAC
Biotechnology: Pharmaceutical Preparations
Health Care
DiaMedica Therapeutics to Provide a Business Update and Report Third Quarter 2024 Financial Results November 14, 2024
DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, announced today that its third quarter 2024 financial results will be released after market close on Wednesday, November 13th. DiaMedica will host a live conference call on Thursday, November 14th at 7:00 AM Central Time to provide a business update and discuss financial results. Conference Call details: Date: Thursday, November 14, 2024 Time: 7:00 AM CT / 8:00 AM ET Web access: https://app.webinar.net/8B2w698qkyb Dial In: (646) 357-8785 Conference ID: 28056 Interested parties may access the conf
11/6/24 8:32:00 AM ET
$DMAC
Biotechnology: Pharmaceutical Preparations
Health Care
DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2024 Financial Results
Conference Call and Webcast August 8 at 8:00 AM Eastern Time / 7:00 AM Central Time Acute Ischemic Stroke (AIS) Phase 2/3 ReMEDy2 Trial Interim Enrollment (n=144) Targeted for Q1 2025 Preeclampsia Phase 2 Investigator-sponsored Trial Beginning in Q4 2024 with Proof-of-Concept Results Targeted for First Half 2025 Completed $12 Million Private Placement, Extending Cash Runway Into Q3 2026 DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today provided a business update and financial results for the quarter ended June 30, 2024. Management will host a conference call Thursday, A
8/7/24 4:15:00 PM ET
$DMAC
Biotechnology: Pharmaceutical Preparations
Health Care

$DMAC
Leadership Updates

Live Leadership Updates

DiaMedica Therapeutics Appoints Dr. Lorianne Masuoka as Chief Medical Officer
Executive with Strong Track Record in Advancing Pipelines Through Clinical Development DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, announced today the appointment of Lorianne Masuoka, M.D. as Chief Medical Officer. Dr. Masuoka is a board-certified neurologist with more than 25 years of experience and a successful track record of managing clinical programs from early stage to drug approvals and strategic alliances. "We are delighted to have Lorianne join our executive leadership team," said Rick Pauls, DiaMedica's President and Chief Executive Officer. "Sh
1/22/24 8:23:00 AM ET
$DMAC
$MRNS
$NKTR
Biotechnology: Pharmaceutical Preparations
Health Care
DiaMedica Therapeutics Announces the Appointment of Ambarish Shah, Ph.D. as Chief Technology Officer
Dr. Shah Has Spent Over Two Decades Leading Biological Development Teams at Biotechnology Companies and Has Deep Expertise in Protein Development and Manufacturing DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, announced today the appointment of Ambarish Shah, Ph.D. as Chief Technology Officer. Dr. Shah will lead the development of DiaMedica's manufacturing operations for the late-stage drug candidate DM199. Since May 2023, Dr. Shah has been advising DiaMedica as it worked through the final resolution of the clinical hold on the investigational new drug applic
9/12/23 8:13:00 AM ET
$DMAC
Biotechnology: Pharmaceutical Preparations
Health Care
DiaMedica Therapeutics Announces Appointment of Dr. Richard Kuntz to the Board of Directors
Recently Retired Medtronic Chief Medical Officer and Chief Scientific Officer with Deep Expertise in Stroke Treatment DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on acute ischemic stroke and other vascular diseases, today announced the appointment of Dr. Richard Kuntz to its Board of Directors effective May 30, 2023. Dr. Richard Kuntz recently retired from Medtronic plc (NYSE:MDT) where he was the Chief Medical Officer & Scientific Officer and a member of the Executive Committee. Prior to that, he served as Senior Vice President and President, Neuromodulation of Medtronic from October 2005 to August 2009. Before joining Medtronic, he was
5/30/23 8:29:00 AM ET
$DMAC
$MDT
Biotechnology: Pharmaceutical Preparations
Health Care
Biotechnology: Electromedical & Electrotherapeutic Apparatus

DiaMedica Therapeutics Releases Preeclampsia White Paper And Announces Key Opinion Leader Webinar On DM199 For The Treatment Of Preeclampsia

Chat with this insight

Recent Analyst Ratings for $DMAC

$DMAC Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

H.C. Wainwright initiated coverage on DiaMedica Therapeutics with a new price target

Craig Hallum resumed coverage on DiaMedica Therapeutics with a new price target

DiaMedica Therapeutics upgraded by Oppenheimer with a new price target

$DMAC Press Releases

Fastest customizable press release news feed in the world

DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2024 Financial Results

DiaMedica Therapeutics Announces Dosing of First Patient in Phase 2 Trial of DM199 in the Treatment of Preeclampsia

DiaMedica Therapeutics to Participate in Upcoming Craig-Hallum 15th Annual Alpha Select Conference

$DMAC Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Large owner Von Koch Thomas bought $3,000,000 worth of shares (1,200,000 units at $2.50) (SEC Form 4)

Large owner Stahlberg Jan bought $3,000,000 worth of shares (1,200,000 units at $2.50) (SEC Form 4)

Wambeke David J. bought $49,200 worth of Voting Common Shares (20,000 units at $2.46), increasing direct ownership by 4% to 527,114 units (SEC Form 4)

$DMAC Market Insights

Live Market Insights

$DMAC Financials

Live finance-specific insights

$DMAC Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

$DMAC Large Ownership Changes

This live feed shows all institutional transactions in real time.

$DMAC SEC Filings